{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:54:46Z","timestamp":1793825686197,"version":"4.6.1"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rmed.2025.108396","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:07:44Z","timestamp":1759540064000},"page":"108396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Anti-inflammatory agents for the management of COPD - Quo Vadis?"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-6800","authenticated-orcid":false,"given":"Agamemnon","family":"Bakakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6393-0982","authenticated-orcid":false,"given":"Zoi","family":"Sotiropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nektarios","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5794-3089","authenticated-orcid":false,"given":"Angelos","family":"Vontetsianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Cholidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9708-3241","authenticated-orcid":false,"given":"Andriana I.","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9657-3705","authenticated-orcid":false,"given":"Konstantinos","family":"Bartziokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00239-2023","article-title":"Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary","volume":"61","author":"Agusti","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/pr.119.018150","article-title":"Pharmacology and therapeutics of bronchodilators revisited","volume":"72","author":"Matera","year":"2020","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12931-024-03051-2","article-title":"Global, regional, and national burden of chronic obstructive pulmonary disease and its attributable risk factors from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021","volume":"26","author":"Wang","year":"2025","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/14740338.2015.1001363","article-title":"Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease","volume":"14","author":"Matera","year":"2015","journal-title":"Expet Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108396_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02265-2016","article-title":"Prevention of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"50","author":"Wedzicha","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","article-title":"Inflammatory mechanisms in patients with chronic obstructive pulmonary disease","volume":"138","author":"Barnes","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2025.108396_bib8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1164\/rccm.201701-0218PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report. GOLD executive summary","volume":"195","author":"Vogelmeier","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10082","key":"10.1016\/j.rmed.2025.108396_bib9","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(17)31222-9","article-title":"Chronic obstructive pulmonary disease","volume":"389","author":"Rabe","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/s-0035-1555611","article-title":"Identifying molecular targets for new drug development for chronic obstructive pulmonary disease: what does the future hold?","volume":"36","author":"Barnes","year":"2015","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-020-00345-x","article-title":"Progress in the mechanism and targeted drug therapy for COPD","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14728214.2020.1819982","article-title":"New drugs under development for COPD","volume":"25","author":"Lo Bello","year":"2020","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.rmed.2025.108396_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coph.2020.11.003","article-title":"Prospects for COPD treatment","volume":"56","author":"Matera","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2","key":"10.1016\/j.rmed.2025.108396_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tibs.2009.09.007","article-title":"Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown","volume":"35","author":"Houslay","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.rmed.2025.108396_bib15","first-page":"147","article-title":"Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD","volume":"4","author":"Giembycz","year":"2010","journal-title":"Drug Des. Dev. Ther."},{"issue":"3","key":"10.1016\/j.rmed.2025.108396_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/jpet.114.220558","article-title":"CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window","volume":"352","author":"Villetti","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.rmed.2025.108396_bib17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3389\/fphar.2019.01337","article-title":"CHF6001 inhibits NF-kappaB activation and neutrophilic recruitment in LPS-Induced lung inflammation in mice","volume":"10","author":"Stellari","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.rmed.2025.108396_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154739","article-title":"The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients","volume":"123","author":"Lea","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.rmed.2025.108396_bib19","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.2147\/COPD.S174156","article-title":"Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers","volume":"13","author":"Mariotti","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12931-019-1142-7","article-title":"Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD","volume":"20","author":"Singh","year":"2019","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12931-020-01512-y","article-title":"Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study","volume":"21","author":"Singh","year":"2020","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12931-020-1329-y","article-title":"Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis","volume":"21","author":"Govoni","year":"2020","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2025.108396_bib23","article-title":"Placebo-controlled study to evaluate the efficacy and safety of 2 doses of CHF6001 DPI (Tanimilast), as add-on to maintenance triple therapy in subjects with COPD and chronic","year":"2025","journal-title":"Bronchitis (PILASTER) (PILASTER)"},{"key":"10.1016\/j.rmed.2025.108396_bib24","article-title":"Placebo- and Active- controlled (Roflumilast, daliresp\u00ae 500\u03bcg) study to evaluate the efficacy and safety of two doses of CHF6001 DPI (Tanimilast) as add-on to maintenance triple therapy in subjects with COPD and chronic bronchitis","year":"2025","journal-title":"PILLAR) (PILLAR)"},{"issue":"154","key":"10.1016\/j.rmed.2025.108396_bib25","article-title":"The future of bronchodilation: looking for new classes of bronchodilators, European respiratory review : an official","volume":"28","author":"Cazzola","year":"2019","journal-title":"J. Eur. Respir. Soc."},{"issue":"5 Pt 1","key":"10.1016\/j.rmed.2025.108396_bib26","first-page":"L458","article-title":"Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization","volume":"264","author":"Rabe","year":"1993","journal-title":"Am. J. Physiol."},{"issue":"5","key":"10.1016\/j.rmed.2025.108396_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bcpt.12209","article-title":"Dual PDE3\/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases","volume":"114","author":"Abbott-Banner","year":"2014","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.rmed.2025.108396_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coph.2014.04.001","article-title":"Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease","volume":"16","author":"Giembycz","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12931-020-1307-4","article-title":"A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD","volume":"21","author":"Singh","year":"2020","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2025.108396_bib30","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2147\/COPD.S263025","article-title":"Symptom improvement following treatment with the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in patients with moderate to severe COPD - a detailed analysis","volume":"15","author":"Watz","year":"2020","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108396_bib31","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2147\/COPD.S307160","article-title":"A dose-ranging study of the novel inhaled dual PDE 3 and 4 inhibitor ensifentrine in patients with COPD receiving maintenance tiotropium therapy","volume":"16","author":"Ferguson","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, Double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.rmed.2025.108396_bib33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/17476348.2024.2389960","article-title":"Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials","volume":"18","author":"Mahler","year":"2024","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.rmed.2025.108396_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/14799731251314874","article-title":"Ensifentrine in COPD patients taking long-acting bronchodilators: a pooled post-hoc analysis of the ENHANCE-1\/2 studies","volume":"22","author":"Dransfield","year":"2025","journal-title":"Chron. Respir. Dis."},{"key":"10.1016\/j.rmed.2025.108396_bib35","article-title":"Ensifentrine: newly approved for maintenance treatment in patients with chronic obstructive pulmonary disease","author":"Kariya","year":"2024","journal-title":"NEJM J. Watch"},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12931-019-1000-7","article-title":"Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial","volume":"20","author":"Brown","year":"2019","journal-title":"Respir. Res."},{"issue":"20","key":"10.1016\/j.rmed.2025.108396_bib37","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.1021\/acs.jmedchem.7b01215","article-title":"Selective nonsteroidal glucocorticoid receptor modulators for the inhaled treatment of pulmonary diseases","volume":"60","author":"Hemmerling","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.rmed.2025.108396_bib38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2147\/DDDT.S334960","article-title":"Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator velsecorat (AZD7594) following inhalation in healthy volunteers","volume":"16","author":"Prothon","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bcpt.12768","article-title":"Efficacy and tolerability of an inhaled selective glucocorticoid receptor modulator - AZD5423 - in chronic obstructive pulmonary disease patients: phase II study results","volume":"121","author":"Kuna","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.rmed.2025.108396_bib40","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/pr.116.012518","article-title":"Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease","volume":"68","author":"Barnes","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.rmed.2025.108396_bib41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acs.jmedchem.6b01634","article-title":"Design and synthesis of a pan-janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin","volume":"60","author":"Jones","year":"2017","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.rmed.2025.108396_bib42","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1021\/acs.jmedchem.9b00533","article-title":"Identification of 2-Imidazopyridine and 2-Aminopyridone purinones as potent pan-janus kinase (JAK) inhibitors for the inhaled treatment of respiratory diseases","volume":"62","author":"Bach","year":"2019","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib43","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1038\/s41598-022-09241-6","article-title":"The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro","volume":"12","author":"Milara","year":"2022","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.rmed.2025.108396_bib44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/25785826.2022.2139317","article-title":"Recent progress of JAK inhibitors for hematological disorders","volume":"46","author":"Kirito","year":"2023","journal-title":"Immunol. Med."},{"key":"10.1016\/j.rmed.2025.108396_bib45","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/DDDT.S300988","article-title":"Role of p38 mitogen-activated protein kinase in asthma and COPD: pathogenic aspects and potential targeted therapies","volume":"15","author":"Pelaia","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/0091270009347873","article-title":"A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients","volume":"50","author":"Singh","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.94","article-title":"Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial","volume":"3","author":"Betts","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib48","first-page":"63","article-title":"Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial, The Lancet","volume":"2","author":"Watz","year":"2014","journal-title":"Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2025.108396_bib49","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.rmed.2015.05.003","article-title":"A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with <\/=2% and >2% blood eosinophils","volume":"109","author":"Marks-Konczalik","year":"2015","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108396_bib50","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0091270010397050","article-title":"An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease","volume":"52","author":"Lomas","year":"2012","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.rmed.2025.108396_bib51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/thoraxjnl-2012-202744","article-title":"Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial","volume":"68","author":"MacNee","year":"2013","journal-title":"Thorax"},{"issue":"5\u20136","key":"10.1016\/j.rmed.2025.108396_bib52","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/15412555.2019.1682535","article-title":"Phase II study of single\/repeated doses of acumapimod (BCT197) to treat acute exacerbations of COPD","volume":"16","author":"Strambu","year":"2019","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108396_bib53","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2147\/COPD.S159936","article-title":"Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells","volume":"13","author":"Higham","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108396_bib54","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2147\/COPD.S150576","article-title":"The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial","volume":"13","author":"Patel","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib55","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00188-2017","article-title":"RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-alpha and -gamma selectivity, suppresses COPD inflammation","volume":"50","author":"Charron","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.rmed.2025.108396_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122058","article-title":"LABAs and p38MAPK inhibitors reverse the corticosteroid-insensitivity of IL-8 in airway smooth muscle cells of COPD","volume":"8","author":"Knobloch","year":"2019","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.rmed.2025.108396_bib57","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1164\/rccm.200906-0937OC","article-title":"Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease","volume":"182","author":"To","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.rmed.2025.108396_bib58","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1164\/rccm.200810-1570OC","article-title":"Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice","volume":"179","author":"Marwick","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108396_bib59","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/path.5696","article-title":"PI3K signalling in chronic obstructive pulmonary disease and opportunities for therapy","volume":"254","author":"Moradi","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.rmed.2025.108396_bib60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.intimp.2016.03.027","article-title":"The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils","volume":"35","author":"Gupta","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.rmed.2025.108396_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pupt.2017.08.008","article-title":"Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kdelta inhibitor under development for the treatment of COPD","volume":"46","author":"Cahn","year":"2017","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"3","key":"10.1016\/j.rmed.2025.108396_bib62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1124\/jpet.118.255109","article-title":"Relationship between pharmacokinetics and pharmacodynamic responses in healthy smokers informs a once-daily dosing regimen for Nemiralisib","volume":"369","author":"Begg","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"8","key":"10.1016\/j.rmed.2025.108396_bib63","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.clinthera.2018.06.011","article-title":"Safety, tolerability, and pharmacokinetics of single and repeat doses of Nemiralisib administered via the ellipta dry powder inhaler to healthy subjects","volume":"40","author":"Wilson","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.rmed.2025.108396_bib64","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2147\/COPD.S309320","article-title":"Nemiralisib in patients with an acute exacerbation of COPD: Placebo-Controlled, dose-ranging Study","volume":"16","author":"Fahy","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib65","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12931-024-02999-5","article-title":"CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD","volume":"25","author":"Govoni","year":"2024","journal-title":"Respir. Res."},{"issue":"13","key":"10.1016\/j.rmed.2025.108396_bib66","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.2174\/0929867327999200819145327","article-title":"Role of atypical chemokines and chemokine receptors pathways in the pathogenesis of COPD","volume":"28","author":"Nucera","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib67","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01020-2018","article-title":"Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD","volume":"52","author":"Lazaar","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib68","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00583-2020","article-title":"CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin","volume":"6","author":"Keir","year":"2020","journal-title":"ERJ open Res."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib69","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12931-020-01401-4","article-title":"CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial","volume":"21","author":"Lazaar","year":"2020","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2025.108396_bib70","article-title":"A pilot Study of danirixin for disease progression in chronic obstructive pulmonary disease","year":"2020","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108396_bib71","author":"Safety"},{"key":"10.1016\/j.rmed.2025.108396_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.109842","article-title":"Nuclear factor-kappa B (NF-kappaB) inhibition as a therapeutic target for plant nutraceuticals in mitigating inflammatory lung diseases","volume":"354","author":"Alharbi","year":"2022","journal-title":"Chem. Biol. Interact."},{"issue":"6","key":"10.1016\/j.rmed.2025.108396_bib73","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nchembio.367","article-title":"Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids","volume":"6","author":"Groeger","year":"2010","journal-title":"Nat. Chem. Biol."},{"issue":"7","key":"10.1016\/j.rmed.2025.108396_bib74","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.bbagen.2014.02.024","article-title":"Dual anti-oxidant and anti-inflammatory actions of the electrophilic cyclooxygenase-2-derived 17-oxo-DHA in lipopolysaccharide- and cigarette smoke-induced inflammation","volume":"1840","author":"Cipollina","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"9795","key":"10.1016\/j.rmed.2025.108396_bib75","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(11)60988-4","article-title":"New insights into the immunology of chronic obstructive pulmonary disease","volume":"378","author":"Brusselle","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2025.108396_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/srep37625","article-title":"17-oxo-DHA displays additive anti-inflammatory effects with fluticasone propionate and inhibits the NLRP3 inflammasome","volume":"6","author":"Cipollina","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.rmed.2025.108396_bib77","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3390\/biom5031266","article-title":"NF-kappaB signaling in chronic inflammatory airway disease","volume":"5","author":"Schuliga","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.rmed.2025.108396_bib78","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2147\/COPD.S419056","article-title":"Novel anti-inflammatory approaches to COPD","volume":"18","author":"Cazzola","year":"2023","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib79","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12674","article-title":"The role of Th1\/Th2 cytokines played in regulation of specific CD4 (+) Th1 cell conversion and activation during inflammatory reaction of chronic obstructive pulmonary disease","volume":"88","author":"Sun","year":"2018","journal-title":"Scand. J. Immunol."},{"issue":"7","key":"10.1016\/j.rmed.2025.108396_bib80","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41577-018-0006-6","article-title":"Targeting cytokines to treat asthma and chronic obstructive pulmonary disease","volume":"18","author":"Barnes","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"26","key":"10.1016\/j.rmed.2025.108396_bib81","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in Moderate-to-Severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.rmed.2025.108396_bib82","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108396_bib83","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.rmed.2025.108396_bib84","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.rmed.2025.108396_bib85","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/d41573-024-00164-7","article-title":"FDA approves first monoclonal antibody for COPD","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.rmed.2025.108396_bib86","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaip.2024.02.007","article-title":"Lebrikizumab in uncontrolled asthma: reanalysis in a well-defined type 2 population","volume":"12","author":"Corren","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.rmed.2025.108396_bib87","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00437-2020","article-title":"Targeted therapy in eosinophilic chronic obstructive pulmonary disease","volume":"7","author":"Fieldes","year":"2021","journal-title":"ERJ open Res."},{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib88","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/resp.12475","article-title":"Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease","volume":"20","author":"Eltboli","year":"2015","journal-title":"Respirology"},{"issue":"17","key":"10.1016\/j.rmed.2025.108396_bib89","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108396_bib90","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108396_bib91","doi-asserted-by":"crossref","unstructured":"I. Pavord, D.J. Jackson, S. Korn, C. Taill\u00e9, K. Miller, D. Mouneimne, J. Min, R. Chan, S. Kolterer, B. Mayer, G.J. Criner, Clinical trial design of biologic therapies in COPD: MATINEE study of mepolizumab, Eur. Respir. J. 64(suppl 68) PA4789.","DOI":"10.1183\/13993003.congress-2024.PA4789"},{"issue":"17","key":"10.1016\/j.rmed.2025.108396_bib92","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108396_bib95","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500012","article-title":"Mepolizumab for COPD with Eosinophilic Phenotype following Hospitalization","author":"Flynn","year":"2025","journal-title":"NEJM evidence"},{"issue":"11","key":"10.1016\/j.rmed.2025.108396_bib96","first-page":"891","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study, The Lancet","volume":"2","author":"Brightling","year":"2014","journal-title":"Respir. Med."},{"issue":"11","key":"10.1016\/j.rmed.2025.108396_bib97","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108396_bib98","first-page":"158","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies, The Lancet","volume":"8","author":"Criner","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108396_bib99","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2147\/COPD.S418944","article-title":"Benralizumab prevents recurrent exacerbations in patients with chronic obstructive pulmonary disease: a post hoc analysis","volume":"18","author":"Singh","year":"2023","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib100","first-page":"59","article-title":"Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial, The Lancet","volume":"13","author":"Ramakrishnan","year":"2025","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108396_bib101","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/JAA.S358738","article-title":"Reliability, satisfaction and effectiveness of benralizumab home self-administration in patients with severe eosinophilic asthma in real-world practice: the auto-benra Study","volume":"15","author":"Garcia-Moguel","year":"2022","journal-title":"J. Asthma Allergy"},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","article-title":"Role of thymic stromal lymphopoietin in allergy and beyond","volume":"23","author":"Ebina-Shibuya","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"19","key":"10.1016\/j.rmed.2025.108396_bib104","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib105","first-page":"47","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial, The Lancet","volume":"13","author":"Singh","year":"2025","journal-title":"Respir. Med."},{"issue":"10","key":"10.1016\/j.rmed.2025.108396_bib106","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108396_bib107","year":"2022","journal-title":"Pharmacodyna. Saf. Patients With COPD"},{"key":"10.1016\/j.rmed.2025.108396_bib108","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3389\/fimmu.2019.00692","article-title":"IL-33 mediated inflammation in chronic respiratory diseases-understanding the role of the member of IL-1 superfamily","volume":"10","author":"Gabryelska","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2025.108396_bib109","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/cpt.3147","article-title":"A randomized phase I Study of the Anti-Interleukin-33 antibody tozorakimab in healthy adults and patients with chronic obstructive pulmonary disease","volume":"115","author":"Reid","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2025.108396_bib110","series-title":"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease with a History of Exacerbations","year":"2025"},{"key":"10.1016\/j.rmed.2025.108396_bib111","article-title":"Long-term efficacy and safety of tozorakimab in participants with chronic obstructive pulmonary disease with a history of exacerbations","year":"2025","journal-title":"PROSPERO). (PROSPERO)"},{"issue":"11","key":"10.1016\/j.rmed.2025.108396_bib112","first-page":"1288","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial, The Lancet","volume":"9","author":"Rabe","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108396_bib113","doi-asserted-by":"crossref","unstructured":"K.F. Rabe, B.R. Celli, A. Praestgaard, M. Djandji, X. Soler, R.M. Abdulai, D.J. Lederer, H. Goulaouic, M.C. Nivens, S. Siddiqui, J.A. Jacob-Nara, Y. Deniz, P.J. Rowe, Itepekimab significantly reduced hospitalizations or emergency department visits in former smokers with moderate-to-severe COPD, Eur. Respir. J. 60(suppl 66) 1230.","DOI":"10.1183\/13993003.congress-2022.1230"},{"issue":"5","key":"10.1016\/j.rmed.2025.108396_bib114","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00718-2023","article-title":"AERIFY-1\/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD","volume":"10","author":"Rabe","year":"2024","journal-title":"ERJ open Res."},{"issue":"5","key":"10.1016\/j.rmed.2025.108396_bib115","first-page":"469","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial, The Lancet","volume":"10","author":"Yousuf","year":"2022","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108396_bib118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/14712598.2022.2160238","article-title":"Biologic therapies for chronic obstructive pulmonary disease","volume":"23","author":"Matera","year":"2023","journal-title":"Expet Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.rmed.2025.108396_bib119","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/15412555.2017.1335697","article-title":"A randomized, placebo-controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease","volume":"14","author":"Eich","year":"2017","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40413-018-0208-1","article-title":"Potential new targets for drug development in severe asthma","volume":"11","author":"Zhu","year":"2018","journal-title":"The World Allergy Organ. J."},{"issue":"21","key":"10.1016\/j.rmed.2025.108396_bib121","doi-asserted-by":"crossref","first-page":"12911","DOI":"10.1021\/acs.jmedchem.0c01285","article-title":"Therapeutic targeting of MMP-12 for the treatment of chronic obstructive pulmonary disease","volume":"63","author":"Baggio","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.rmed.2025.108396_bib122","first-page":"169","article-title":"Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate\/severe COPD: a randomised controlled trial, Pulmonary","volume":"25","author":"Dahl","year":"2012","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.rmed.2025.108396_bib123","article-title":"Pharmacokinetics of Andecaliximab in adults with chronic obstructive pulmonary disease","author":"Safety","year":"2020","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib124","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40261-020-00981-9","article-title":"First-in-Man safety, tolerability, and pharmacokinetics of a novel and highly selective inhibitor of matrix Metalloproteinase-12, FP-025: results from two randomized studies in healthy subjects","volume":"41","author":"Abd-Elaziz","year":"2021","journal-title":"Clin. Drug Invest."},{"issue":"22","key":"10.1016\/j.rmed.2025.108396_bib125","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.rmed.2025.108396_bib126","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108396_bib127","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/15412555.2011.641803","article-title":"A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium","volume":"9","author":"Vogelmeier","year":"2012","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108396_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109537","article-title":"Inhibition of neutrophil elastase prevents cigarette smoke exposure-induced formation of neutrophil extracellular traps and improves lung function in a mouse model of chronic obstructive pulmonary disease","volume":"114","author":"Wang","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.rmed.2025.108396_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/biom11081065","article-title":"Neutrophil elastase and chronic lung disease","volume":"11","author":"Voynow","year":"2021","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.rmed.2025.108396_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0095-0","article-title":"Topical small molecule granzyme B inhibitor improves remodeling in a murine model of impaired burn wound healing","volume":"50","author":"Shen","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.rmed.2025.108396_bib131","series-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease","year":"2025"},{"key":"10.1016\/j.rmed.2025.108396_bib132","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/802189","article-title":"Effect of the Zataria multiflora on systemic inflammation of experimental animals model of COPD","volume":"2014","author":"Boskabady","year":"2014","journal-title":"BioMed Res. Int."},{"issue":"7","key":"10.1016\/j.rmed.2025.108396_bib133","doi-asserted-by":"crossref","DOI":"10.5812\/ircmj.10421","article-title":"Nigella sativa pretreatment in Guinea pigs exposed to cigarette smoke modulates in vitro tracheal responsiveness","volume":"16","author":"Keyhanmanesh","year":"2014","journal-title":"Iran. Red Crescent Med. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib134","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pharep.2014.08.017","article-title":"The effect of carvacrol on systemic inflammation in guinea pigs model of COPD induced by cigarette smoke exposure","volume":"67","author":"Mahtaj","year":"2015","journal-title":"Pharmacol. Rep. : PR"},{"key":"10.1016\/j.rmed.2025.108396_bib135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12906-015-0574-y","article-title":"Lung inflammation changes and oxidative stress induced by cigarette smoke exposure in guinea pigs affected by Zataria multiflora and its constituent, carvacrol","volume":"15","author":"Boskabady","year":"2015","journal-title":"BMC Compl. Alternative Med."},{"key":"10.1016\/j.rmed.2025.108396_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.117928","article-title":"Zataria multiflora affects pulmonary function tests, respiratory symptoms, bronchodilator drugs use and hematological parameters in chronic obstructive pulmonary disease patients: a randomized doubled-blind clinical trial","volume":"326","author":"Ghorani","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.rmed.2025.108396_bib137","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.2147\/COPD.S106370","article-title":"Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis","volume":"11","author":"Yuan","year":"2016","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108396_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107863","article-title":"Safety and efficacy of ensifentrine in COPD: a systemic review and meta-analysis","volume":"236","author":"Yappalparvi","year":"2025","journal-title":"Respir. Med."},{"issue":"6","key":"10.1016\/j.rmed.2025.108396_bib139","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/cpt.1058","article-title":"Evaluation of potential disease-mediated drug-drug interaction in patients with Moderate-to-Severe atopic dermatitis receiving dupilumab","volume":"104","author":"Davis","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.rmed.2025.108396_bib140","article-title":"Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study","volume":"66","author":"Sheng-Kai Ma","year":"2025","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2025.108396_bib141","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2024.03.039","article-title":"Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study","volume":"91","author":"Hasan","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9","key":"10.1016\/j.rmed.2025.108396_bib142","first-page":"2058","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center","volume":"38","author":"Lugogo","year":"2016","journal-title":"Open-label, Phase IIIb Study Clin. Therapeut."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib143","first-page":"46","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial, The Lancet","volume":"7","author":"Busse","year":"2019","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108396_bib144","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003583","article-title":"Anti-IL-5 biologics and rheumatoid arthritis: a single-centre 500 patient year exposure analysis","volume":"9","author":"Dean","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib145","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.rmed.2025.108396_bib146","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2024.2387317","article-title":"Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA Adverse Event reporting System","volume":"24","author":"Lin","year":"2025","journal-title":"Expet Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib147","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s13287-024-03940-9","article-title":"Stem cell therapies for chronic obstructive pulmonary disease: mesenchymal stem cells as a promising treatment option","volume":"15","author":"Lai","year":"2024","journal-title":"Stem Cell Res. Ther."},{"issue":"2","key":"10.1016\/j.rmed.2025.108396_bib148","article-title":"The role of gene therapy as an emerging treatment strategy for Alpha-1 antitrypsin deficiency-associated lung disease: a systematic review","volume":"17","author":"Afrin","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.rmed.2025.108396_bib149","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1164\/rccm.202403-0473PP","article-title":"The precision medicine era of bronchiectasis","volume":"210","author":"Chotirmall","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.rmed.2025.108396_bib150","article-title":"Gut Microbiota modulation in the management of chronic obstructive pulmonary disease: a literature review","volume":"16","author":"Patibandla","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.rmed.2025.108396_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e25393","article-title":"The application of nanoparticles as advanced drug delivery systems in Attenuating COPD","volume":"10","author":"Jessamine","year":"2024","journal-title":"Heliyon"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125004597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125004597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:10:44Z","timestamp":1761117044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125004597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":146,"alternative-id":["S0954611125004597"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108396","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-inflammatory agents for the management of COPD - Quo Vadis?","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108396"}}